On Thursday 6 December, Vrije Universiteit Amsterdam (VU) and Deloitte formalized their intention to underline the collaboration for the further development of the Care robot.
In the collaboration with Deloitte, further steps will be taken in the further development of the prototype known as Alice 2.0. The aim is a robotic solution for health care, which is based on the earlier developed robot and software in the VU research group SELEMCA, led by Johan Hoorn and Elly Konijn, which can help in the prevention of loneliness amongst elderly people.
Within the VU, the activities focus primarily on fundamental and applied research in social robotics. Researchers from different disciplines, such as Media Psychology from Communication Science and AI from Informatics work together on this project. Students can follow a cross-disciplinary master track ‘Socially Aware Robotics’ as of September. Three student groups are already working together with Deloitte to carry out their research project, on the one hand focusing on so-called ‘user tests’, ‘design’ and ‘engeneering’, on the other hand on policy and implementation, as well as marketing.
Deloitte and VU will focus on the further development of user research, concept creation and the development of the design and software of the Care Robot.
IXA VU-VUmc business developers and legal counsel have supported the creation of this collaboration.
MedTech startup Sirius Medical has received CE Mark approval for Sirius Pintuition, a non-radioactive device to localize breast tumors. In 2016 Bram Schermers, then a scientist at NKI, pitched an early concept at the annual Amsterdam Science & Innovation Awards and won first prize! His pitch also caught the attention of seasoned entrepreneur Hubert Martens, […]News
An annual survey held by the program directors of the Joint Master Entrepreneurship (UvA/ VU), Bram Kuijken and Enno Masurel, has found that 17.8% of alumni have founded their own company and 11.0% are currently working freelance. Additionally, the study found that 41.9% of alumni is employed by a startup (19.7%) or a scale-up (22.2%). […]News
CimCure, a spin-off of Amsterdam UMC and focusing on cancer immunotherapies for solid tumors, signed a strategic partnership agreement for in-licensing CimCure’s iBoost technology with Intravacc, a worldwide leading translational research and development vaccine organization with an extensive track record in developing viral and bacterial vaccines. The iBoost (immune boost) technology was developed at Amsterdam […]News